Navigation Links
Lightlake Therapeutics Inc. Announces Positive Final Phase II Clinical Trial Results of Binge Eating Disorder Treatment
Date:8/8/2012

LONDON, Aug. 8, 2012 /PRNewswire/ -- Lightlake Therapeutics Inc. (OTCBB: LLTP) (the "Company" or "Lightlake"), an early stage biopharmaceutical company developing modern addiction treatments based on its expertise using opioid antagonists, announced today compelling final data from a Phase II study of the Company's proprietary opioid antagonist naloxone nasal spray treatment for patients with Binge Eating Disorder (BED). BED is a psychiatric condition that is manifested by recurrent episodes of eating unusually large amounts of food in a short period of time associated with a sense of lack of control over food intake.

BED is a major cause of obesity for those patients with addictive behavior towards food. It is the most chronic and common of all eating disorders with a significant cost to society, with 12 to 18 million people in the United States likely meeting the criteria for BED and a further 20 million people exhibiting bingeing behavior. It is significantly undertreated with no approved pharmacological therapies.

Patients receiving the naloxone nasal spray achieved the study's primary endpoint by exhibiting a statistically significant reduction in time spent per week binge eating compared to those patients who received a placebo nasal spray, reducing their bingeing by 125 minutes per week compared to 84 minutes per week for placebo-treated subjects (p=0.024).

The effect of the naloxone nasal spray was especially pronounced when comparing the baseline bingeing with the level of bingeing during the last week of treatment, with the patients receiving naloxone reducing their bingeing by 158 minutes per week compared to 101 minutes per week for placebo-treated subjects (p=0.018) during this period. Overall, 81% of patients completed the entire six-month study with no statistically significant difference in dropout rates between the placebo and the treatment groups and without any Serious Adverse Events (SAE) reported during the trial.
'/>"/>

SOURCE Lightlake Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Hepatitis B Therapeutics - Pipeline Assessment and Market Forecasts to 2019
2. Celltex Therapeutics Corporation Expands Laboratory Operations And Adds Depth To Its Management Team
3. Karyopharm Therapeutics announces the Publication of Two Preclinical Studies on the Activity of Selective Inhibitors of Nuclear Export (SINE) in Acute Myeloblastic Leukemia (AML)
4. Cell Therapeutics, Inc. (CTI) to Report Second Quarter Financial Results on August 1
5. United Therapeutics Corporation Reports Second Quarter 2012 Financial Results
6. Relmada Therapeutics Raises $3.0 Million In Initial Closing Of Series A Financing
7. United Therapeutics Corporation to Announce Second Quarter 2012 Financial Results Before Market Open on Thursday, July 26, 2012
8. Juventas Therapeutics Raises $22.2 Million Series B Financing
9. Silence Therapeutics Announces Subscription and Open Offer to Raise up to £5.7 Million
10. Nektar Therapeutics Announces Private Placement of $125 Million of Senior Secured Notes Due in 2017
11. Bio-Innovator Saneron CCEL Therapeutics Supports Cryo-Cell International Leadership and Board of Directors in Proxy Contest
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014  U.S. biotech company ... signing an exclusive license for technology developed by the ... gene expression in plants, including for applications in production ... The technology was developed under the direction ... at Kultevat and former president of the Danforth Plant ...
(Date:9/18/2014)... , Sept. 18, 2014   Sigma-Aldrich ... today it has entered into a new gene ... Medical School,s Vector Core. Under the partnership, Sigma-Aldrich ... technology, experimental design consultation, and dedicated gene editing ... accelerate gene editing-based research at the U-M Medical ...
(Date:9/18/2014)... sweeteners, promoted as aids to weight loss and diabetes ... and metabolic disease; and they do it in a ... the gut microbiota the substantial population of bacteria ... experiments in mice and humans, were published today in ... Elinav of the Weizmann Institute,s Immunology Department, who led ...
(Date:9/18/2014)... September 18, 2014 Pipette.com announces ... Sartorius/Biohit, Socorex, Capp, and AccuPet brand of pipettes. ... 100 uL or less and are a great ... applications. , The micropipette promotions were designed ... economic alternative products to help customers find the ...
Breaking Biology Technology:Kultevat obtains license of gene switch technology 2Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 2Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 3Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 4Gut bacteria, artificial sweeteners and glucose intolerance 2Gut bacteria, artificial sweeteners and glucose intolerance 3Major Pipette Distributor Pipette.com Announces Promotions on Sartorius/Biohit, Socorex, Capp, and AccuPet Micropipettes 2Major Pipette Distributor Pipette.com Announces Promotions on Sartorius/Biohit, Socorex, Capp, and AccuPet Micropipettes 3
... on its recent analysis of new products within the ... the 2012 North American Frost & Sullivan Award for ... a "gold standard" polymerase chain reaction (PCR) instrument. The ... amplification, and detection, all in a multiplexed, automated, and ...
... Inc. (NYSE Amex: BONE ), a leader in ... for medical applications, today announced its financial results for the ... Fourth Quarter 2011 Highlights: Revenue ... for the fourth quarter of 2010. Operating loss decreased ...
... March 21, 2012 When deciding between the ... the upcoming and existing research programs prove highly ... introduces the Life Sciences Content: Pharmaceuticals, Biotechnology, ... to 2012 compendium.  This resource includes Frost ...
Cached Biology Technology:Frost & Sullivan Recognizes iCubate for Developing the New Gold Standard Instrument in the PCR Market 2Frost & Sullivan Recognizes iCubate for Developing the New Gold Standard Instrument in the PCR Market 3Frost & Sullivan Recognizes iCubate for Developing the New Gold Standard Instrument in the PCR Market 4Bacterin Announces Record 2011 Revenue of $30.1 Million; Up 96% Year-over-Year 2Bacterin Announces Record 2011 Revenue of $30.1 Million; Up 96% Year-over-Year 3Bacterin Announces Record 2011 Revenue of $30.1 Million; Up 96% Year-over-Year 4Bacterin Announces Record 2011 Revenue of $30.1 Million; Up 96% Year-over-Year 5Bacterin Announces Record 2011 Revenue of $30.1 Million; Up 96% Year-over-Year 6Bacterin Announces Record 2011 Revenue of $30.1 Million; Up 96% Year-over-Year 7Bacterin Announces Record 2011 Revenue of $30.1 Million; Up 96% Year-over-Year 8Bacterin Announces Record 2011 Revenue of $30.1 Million; Up 96% Year-over-Year 9Bacterin Announces Record 2011 Revenue of $30.1 Million; Up 96% Year-over-Year 10Frost & Sullivan Announces Cutting Edge Life Sciences Research on the Horizon 2Frost & Sullivan Announces Cutting Edge Life Sciences Research on the Horizon 3
(Date:9/16/2014)... 2014)More than $100 trillion in cumulative public and ... dioxide (CO2)a 40 percent reduction of urban passenger ... world expands public transportation, walking and cycling in ... the University of California, Davis, and the Institute ... Further, an estimated 1.4 million early deaths could ...
(Date:9/16/2014)... biology taught us that we inherit certain traits from ... could change how these genes play out by taking ... That,s exactly what a team of researchers at ... through their research of epigenetics research. , Epigenetics ... modifying DNA and histone proteins, which prevent permanent mutations ...
(Date:9/16/2014)... dinosaurs 66 million years ago decimated the evergreens among ... their deciduous peers, according to a study led by ... PLOS Biology . , Applying biomechanical formulas ... of angiosperms flowering plants excluding conifers ... a diverse plant community thriving during a 2.2 million-year ...
Breaking Biology News(10 mins):Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 2Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 3Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 4Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 5Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 2Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 3Meteorite that doomed dinosaurs remade forests 2Meteorite that doomed dinosaurs remade forests 3Meteorite that doomed dinosaurs remade forests 4
... known as 'tandem running' to lead another ant from the ... control both the speed and course of the run. It ... 'formal' teaching has been recognised in any non-human animal. , ... information, rather than the constraint of brain size, that has ...
... Neil Ferguson, and Geoff Garnett (of Imperial College London) ... not be controlled through antiretroviral drugs alone, even if ... article in the open-access international medical journal PLoS Medicine, ... their communities about safe sex, access to drugs is ...
... Hopkins researchers have discovered a gene in fruit flies ... bright light. The study, published in the April 4 ... sensory perception in mammals. , In teasing apart the ... studied a gene they dubbed "Lazaro" that is expressed ...
Cached Biology News:First demonstration of 'teaching' in non-human animals 2Access to antiretrovirals unlikely to reduce HIV infection rates 2New gene reduces retinal degeneration in fruit flies 2
Request Info...
... Bean Nuclease catalyzes the degradation of single-stranded ... terminated products. While the nuclease prefers ssDNA ... concentrations the enzyme degrades double-stranded DNA from ... been used for transcript mapping studies (3,4), ...
... fosmid (40kb), and large plasmid insert (10-20kb) ... BAC vector. On command 20-50 fold copy ... DNA purification. Available with blue-white screening (pEZ ... the highest insert stability. Kits include electrocompetent ...
...
Biology Products: